Evidence map›Paper›PMID 40302433›Full record

ArticleSubstance use & addiction journal2025

Benzodiazepines and Opioid co-use Among Rural People Who Use Drugs: Findings From the Rural Opioid Initiative.

L Sarah Mixson, Arvind Venkataraman, Lydia N Drumright, Bridget M Whitney, Wiley D Jenkins, Peter D Friedmann, William A Zule, Jennifer Havens, Stephanie A Ruderman, Thomas J Stopka and 11 more

Abstract read
In one paragraph

Article in Substance use & addiction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

L Sarah MixsonDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0009-0006-5149-8859
Arvind VenkataramanDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Lydia N DrumrightDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Bridget M WhitneyDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Wiley D JenkinsDepartment of Public Health Sciences, Clemson University, Clemson, SC, USA.
Peter D FriedmannOffice of Research, UMass Chan Medical School - Baystate and Baystate Health, Springfield, MA, USA.
William A ZuleRTI International, Research Triangle Park, NC, USA.
Jennifer HavensUniversity of Kentucky, Lexington, KY, USA.
Stephanie A RudermanDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Thomas J StopkaDepartment of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.
P Todd KorthuisDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Mai T PhoBiological Sciences Division, University of Chicago, Chicago, IL, USA.
Ryan P WestergaardUniversity of Wisconsin-Madison, Madison, WI, USA.
David W SealTulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Vivian F GoUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
William C MillerUniversity of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Judith FeinbergWest Virginia University, Morgantown, WV, USA.
Gordon SmithWest Virginia University, Morgantown, WV, USA.
Judith I TsuiDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Joseph A DelaneyDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Heidi M CraneDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UH3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D, STOPKA, THOMAS J · 2019 to 2022
$3.9M
Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)U24DA048538 · NIDA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., TSUI, JUDITH · 2019 to 2023
$3.7M
Next-Generation Sequencing Center for GHOSTing Hepatitis C Virus: Transforming Community Based Molecular Surveillance and Outbreak InvestigationU24DA044801 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2017 to 2022
$3.3M
Community-based, client-centered prevention homes to address the rural opioid epidemicUH3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2019 to 2022
$2.6M
Learning from the COVID-19 pandemic to improve emergency management planning for harm reduction services in rural OhioUH3DA044822 · NIDA · OHIO STATE UNIVERSITY · PI GO, VIVIAN F., MILLER, WILLIAM C · 2019 to 2022
$2.5M
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern AppalachiaUH3DA044823 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI ZULE, WILLIAM A · 2019 to 2021
$2.4M
Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE)UG3DA044830 · NIDA · BAYSTATE MEDICAL CENTER, INC. · PI FRIEDMANN, PETER D · 2017 to 2018
$1.6M
Community-based, client-centered prevention homes to address the rural opioid epidemicUG3DA044826 · NIDA · UNIVERSITY OF WISCONSIN-MADISON · PI SEAL, DAVID W, WESTERGAARD, RYAN PATRICK · 2017 to 2018
$1.4M
NIAID NIH HHS P30 AI027757NIDA NIH HHS U24 DA044801NIDA NIH HHS U24 DA048538NIDA NIH HHS UG3 DA044798NIDA NIH HHS UG3 DA044822NIDA NIH HHS UG3 DA044823NIDA NIH HHS UG3 DA044825NIDA NIH HHS UG3 DA044826NIDA NIH HHS UG3 DA044829NIDA NIH HHS UG3 DA044830NIDA NIH HHS UG3 DA044831NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044822NIDA NIH HHS UH3 DA044823NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

backgroundBenzodiazepines and opioids are among the most frequently misused psychoactive substances, but their patterns of co-use (polysubstance use) in rural areas are unclear. As resources to address substance use are disproportionally scarce in rural areas, a better understanding of this polysubstance use is critical to allocate and direct interventions.

methodsThe Rural Opioid Initiative comprises 8 research cohorts spanning 10 states and 65 rural counties. Participants were recruited from January 2018 to March 2020 and eligibility included past 30-day opioid use by any route or past 30-day injection of any substance. Analyses were restricted to participants reporting past 30-day opioid use and either benzodiazepine or stimulant use. We described bivariate cross-sectional associations between benzodiazepine+opioid use, compared with stimulant+opioid use, and substance use behaviors, health outcomes, injection drug use, addiction treatment, and criminal legal system involvement.

resultsOf the 1107 ROI participants that met inclusion criteria, 10% (n = 107) reported benzodiazepine+opioid use, and 90% (n = 1000) reported stimulant+opioid use. The benzodiazepine+opioid group, compared with the stimulant+opioid group, had a higher use of opioid pain medication (73% vs 55%), gabapentin (43% vs 23%), and clonidine (12% vs 4%) to get high and used these substances more frequently; they also reported more frequent heavy episodic drinking (6.1 days per 30 days, SD = 9.4 vs 4.1 days, SD 7.5). The benzodiazepine+opioid group reported a lower prevalence in the past 6 months of law enforcement stop-and-search incidents (29% vs 48%), arrests (11% vs 28%), probation (22% vs 34%), jail/prison (18% vs 41%), and fewer days in jail/prison (4.7, SD = 19.1 days vs 15.9, SD = 35.7 days).

conclusionWe found that benzodiazepines+opioids use was associated with more heavy episodic drinking and gabapentin use, and lower prevalence of criminal legal system involvement. These data suggest that individuals reporting benzodiazepines+opioids use have distinct behavioral patterns and outcomes that require targeted interventions for rural populations.

Indexed as

Analgesics, OpioidBenzodiazepinesOpioid-Related DisordersRural PopulationSubstance-Related DisordersAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedUnited StatesYoung AdultAnalgesics, OpioidBenzodiazepinesalcohol drinkingbenzodiazepinescriminal justicedrug overdosegabapentinopioid overdoseopioid-related disorderspolysubstance useprescription drug misuserural population

Identifiers

PMID40302433
PMCPMC12707857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.